Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II home-based alectinib study in locally advanced or metastatic ALK-positive solid tumors
2021-002352-36Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alectinib in solid neoplasms, sponsored by Roche. Started Mar 2022; status: completed.
02
Drugs
alectinib
03
Conditions
solid neoplasms
Beyond the preview
Go deeper on 2021-002352-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002352-36.